<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">Mol Cancer</journal-id><journal-title>Molecular Cancer</journal-title><issn pub-type="epub">1476-4598</issn><publisher><publisher-name>BioMed Central</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">1476-4598-7-53</article-id><article-id pub-id-type="pmid">18541010</article-id><article-id pub-id-type="doi">10.1186/1476-4598-7-53</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>Stabilizing mutation of <italic>CTNNB1</italic>/beta-catenin and protein accumulation analyzed in a large series of parathyroid tumors of Swedish patients</article-title></title-group><contrib-group><contrib id="A1" contrib-type="author"><name><surname>Bj&#x000f6;rklund</surname><given-names>Peyman</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>peyman.bjorklund@surgsci.uu.se</email></contrib><contrib id="A2" contrib-type="author"><name><surname>Lindberg</surname><given-names>Daniel</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>daniel.lindberg@surgsci.uu.se</email></contrib><contrib id="A3" contrib-type="author"><name><surname>&#x000c5;kerstr&#x000f6;m</surname><given-names>G&#x000f6;ran</given-names></name><email>goran.akerstrom@surgsci.uu.se</email></contrib><contrib id="A4" corresp="yes" contrib-type="author"><name><surname>Westin</surname><given-names>Gunnar</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>gunnar.westin@surgsci.uu.se</email></contrib></contrib-group><aff id="I1"><label>1</label>Department of Surgical Sciences, Endocrine Unit, Uppsala University, Uppsala University Hospital, SE-751 85 Uppsala, Sweden</aff><pub-date pub-type="collection"><year>2008</year></pub-date><pub-date pub-type="epub"><day>9</day><month>6</month><year>2008</year></pub-date><volume>7</volume><fpage>53</fpage><lpage>53</lpage><ext-link ext-link-type="uri" xlink:href="http://www.molecular-cancer.com/content/7/1/53"/><history><date date-type="received"><day>26</day><month>2</month><year>2008</year></date><date date-type="accepted"><day>9</day><month>6</month><year>2008</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2008 Bj&#x000f6;rklund et al; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2008</copyright-year><copyright-holder>Bj&#x000f6;rklund et al; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0"/>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</p><!--<rdf xmlns="http://web.resource.org/cc/" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:dc="http://purl.org/dc/elements/1.1" xmlns:dcterms="http://purl.org/dc/terms"><Work xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" rdf:about=""><license rdf:resource="http://creativecommons.org/licenses/by/2.0"/><dc:type rdf:resource="http://purl.org/dc/dcmitype/Text"/><dc:author> Bj&#x000f6;rklund Peyman peyman.bjorklund@surgsci.uu.se </dc:author><dc:title> Stabilizing mutation of CTNNB1/beta-catenin and protein accumulation analyzed in a large series of parathyroid tumors of Swedish patients </dc:title><dc:date>2008</dc:date><dcterms:bibliographicCitation>Molecular Cancer 7(1): 53-. (2008)</dcterms:bibliographicCitation><dc:identifier type="sici">1476-4598(2008)7:1&#x0003c;53&#x0003e;</dc:identifier><dcterms:isPartOf>urn:ISSN:1476-4598</dcterms:isPartOf><License rdf:about="http://creativecommons.org/licenses/by/2.0"><permits rdf:resource="http://web.resource.org/cc/Reproduction" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/Distribution" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Notice" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Attribution" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/DerivativeWorks" xmlns=""/></License></Work></rdf>--></license></permissions><abstract><sec><title>Background</title><p>Aberrant accumulation of &#x003b2;-catenin plays an important role in a variety of human neoplasms. We recently reported accumulation of &#x003b2;-catenin in parathyroid adenomas from patients with primary hyperparathyroidism (pHPT). In <italic>CTNNB1 </italic>exon 3, we detected a stabilizing mutation (S37A) in 3 out of 20 analyzed adenomas. The aim of the present study was to determine the frequency and zygosity of mutations in <italic>CTNNB1 </italic>exon 3, and &#x003b2;-catenin accumulation in a large series of parathyroid adenomas of Swedish patients.</p></sec><sec><title>Results</title><p>The mutation S37A (TCT &#x0003e; GCT) was detected by direct DNA sequencing of PCR fragments in 6 out of 104 sporadic parathyroid adenomas (5.8%). Taking our previous study into account, a total of 9 out of 124 (7.3%) adenomas displayed the same mutation. The mutations were homozygous by DNA sequencing, restriction enzyme cleavage, and gene copy number determination using the GeneChip 500 K Mapping Array Set. All tumors analyzed by immunohistochemistry, including those with mutation, displayed aberrant &#x003b2;-catenin accumulation. Western blotting revealed a slightly higher expression level of &#x003b2;-catenin and nonphosphorylated active &#x003b2;-catenin in tumors with mutation compared to those without. Presence of the mutation was not related to distinct clinical characteristics.</p></sec><sec><title>Conclusion</title><p>Aberrant accumulation of &#x003b2;-catenin is very common in parathyroid tumors, and is caused by stabilizing homozygous mutation in 7.3% of Swedish pHPT patients.</p></sec></abstract></article-meta></front><body><sec><title>Background</title><p>Parathyroid disease with hypersecretion of parathyroid hormone and generally also hypercalcemia occurs in primary hyperparathyroidism (pHPT), due to growth regulatory disturbance in one or several parathyroid glands. Activation of <italic>CCND1 </italic>oncogene expression or inactivation of the <italic>MEN1 </italic>tumor suppressor gene contributes to deregulated growth control in a fraction of sporadic parathyroid adenomas [<xref ref-type="bibr" rid="B1">1</xref>-<xref ref-type="bibr" rid="B4">4</xref>].</p><p>Activation of the Wnt/&#x003b2;-catenin signaling pathway by aberrant accumulation of stabilized &#x003b2;-catenin is involved in the development of many neoplasms. &#x003b2;-catenin accumulation is typically caused by mutations in components of the signaling pathway, such as APC, Axin, &#x003b2;-Trcp, and WTX, or results from secondary events. In addition, protein stabilizing mutations in the glycogen synthase kinase 3&#x003b2; phosphorylation sites of &#x003b2;-catenin (Ser-33, Ser-37, Thr-41, Ser-45) occur with varying frequency in several neoplasms [<xref ref-type="bibr" rid="B5">5</xref>-<xref ref-type="bibr" rid="B9">9</xref>].</p><p>We recently reported activation of the Wnt/&#x003b2;-catenin signaling pathway by aberrant accumulation of &#x003b2;-catenin in parathyroid adenomas from patients with pHPT [<xref ref-type="bibr" rid="B10">10</xref>]. The accumulation of &#x003b2;-catenin was caused by expression of an aberrantly spliced internally truncated Wnt receptor LRP5 or by a stabilizing mutation (S37A) in <italic>CTNNB1 </italic>exon 3 [<xref ref-type="bibr" rid="B10">10</xref>,<xref ref-type="bibr" rid="B11">11</xref>]. Stabilizing mutations of <italic>CTNNB1 </italic>have not been detected in parathyroid adenomas of patients from Japan and the United States [<xref ref-type="bibr" rid="B12">12</xref>,<xref ref-type="bibr" rid="B13">13</xref>]. Here we have determined the frequency and zygosity of mutations in exon 3 of <italic>CTNNB1</italic>, and &#x003b2;-catenin expression status in a large series of parathyroid adenomas of Swedish patients.</p></sec><sec sec-type="methods"><title>Methods</title><sec><title>Tissue Specimens</title><p>Sporadic parathyroid adenomas (n = 104) were acquired from 104 Swedish patients with pHPT diagnosed and operated on in the clinical routine at the Uppsala University Hospital. Normal parathyroid tissue was obtained as normal gland biopsies in patients subjected to parathyroidectomy. Tissues were intraoperatively snap frozen. Informed consent and approval of institutional ethical committee were obtained.</p></sec><sec><title>DNA Sequencing</title><p>DNA from parathyroid tumors was prepared by standard procedures including proteinase K treatment and phenol extraction. Blood DNA was prepared using the Wizard Genomic DNA Purification Kit (Promega Corp., Madison, WI). DNA was PCR amplified with primers for exon 3 of <italic>CTNNB1</italic>. PCR forward primer: 5'-TGA TGG AGT TGG ACA TGG CC; reverse: 5'-CTC ATA CAG GAC TTG GGA GG. The complementary strand was also sequenced for fragments with mutation. The PCR fragments were sequenced directly on the 3130<italic>xl </italic>Genetic Analyzer using the ABI Prism Dye Terminator Cycle Sequencing Ready Reaction kit (Applied Biosystems, Foster City, CA).</p></sec><sec><title>Restriction Enzyme Digestion</title><p><italic>CTNNB1 </italic>exon 3 PCR fragments were purified using the GFX PCR DNA and Gel Band Purification Kit (GE Healthcare Europe GmbH, Uppsala, Sweden) and cleaved with Xma I or Nla III according to instructions by the manufacturer (New England Biolabs, Inc., Beverly, MA). Products were analyzed by agarose gel electrophoresis.</p></sec><sec><title>CTNNB1 Gene Copy Number</title><p>Tumor (S37A) and blood DNA from 4 patients were extracted as described above. DNA was marked with fluorescence dye and hybridized to the Affymetrix GeneChip Mapping 500 K Set Arrays 250K_Nsp_SNP and 250K_Sty_SNP according to the manufacturer's instructions, and analysed by GeneChip Genotyping Analysis Software (GTYPE) using Chromosome Copy Number Analysis Tool (CNAT) (Affymetrix, Inc. Santa Clara, California, USA). Informative SNPs used in the gene copy number determination are shown in Table <xref ref-type="table" rid="T1">1</xref>. The experiment was performed at the Bioinformatics and Expression Analysis core facility at NOVUM, Karolinska Institute, Huddinge, Sweden.</p><table-wrap position="float" id="T1"><label>Table 1</label><caption><p>SNP genotyping</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="center"><bold>SNP position</bold></td><td align="center"><bold>refSNP ID</bold></td><td align="center"><bold>Patient 1</bold></td><td align="center"><bold>Patient 2</bold></td><td align="center"><bold>Patient 3</bold></td><td align="center"><bold>Patient 4</bold></td></tr></thead><tbody><tr><td align="center">41205658</td><td align="center">rs7630377</td><td align="center">ECN</td><td align="center">ECN</td><td align="center">ECN</td><td align="center">ECN</td></tr><tr><td align="center">41209520</td><td align="center">rs9859392</td><td align="center">ECN</td><td align="center">ECN</td><td align="center">ECN</td><td align="center">ECN</td></tr><tr><td align="center">41218746</td><td align="center">rs3915129</td><td align="center">ECN</td><td align="center">NI</td><td align="center">ECN</td><td align="center">ECN</td></tr><tr><td align="center">41237448</td><td align="center">rs13072632</td><td align="center">ECN</td><td align="center">ECN</td><td align="center">ECN</td><td align="center">ECN</td></tr><tr><td align="center">41243358</td><td align="center">rs11564447</td><td align="center">ECN</td><td align="center">ECN</td><td align="center">NI</td><td align="center">ECN</td></tr><tr><td align="center">41262697</td><td align="center">rs9824212</td><td align="center">ECN</td><td align="center">ECN</td><td align="center">ECN</td><td align="center">ECN</td></tr><tr><td align="center">41268711</td><td align="center">rs1880480</td><td align="center">ECN</td><td align="center">ECN</td><td align="center">ECN</td><td align="center">ECN</td></tr></tbody></table><table-wrap-foot><p>Constitutional DNA and parathyroid adenoma DNA with <italic>CTNNB1 </italic>mutation S37A from 4 pHPT patients were genotyped with the GeneChip 500 K Mapping Array Set. The <italic>CTNNB1 </italic>gene is located between positions 41216016 and 41256928 <ext-link ext-link-type="uri" xlink:href="http://genome.ucsc.edu"/>. ECN, equal copy number. NI, non-informative.</p></table-wrap-foot></table-wrap></sec><sec><title>Immunohistochemistry and Western Blotting</title><p>Frozen tissue sections were stained as described [<xref ref-type="bibr" rid="B10">10</xref>] using an anti-&#x003b2;-catenin goat polyclonal antibody with an epitope mapping at the C-terminus (Santa Cruz Biotechnology, INC., Santa Cruz, CA; catalog no. sc-1496). Protein extracts for Western blotting were prepared [<xref ref-type="bibr" rid="B10">10</xref>] in Cytobuster Protein Extract Reagent (Novagen Inc., Madison, Wisconsin, USA) supplemented with Complete protease inhibitor cocktail (Roche Diagnostics GmbH, Penzberg, Germany). The anti-active (nonphosphorylated) &#x003b2;-catenin [<xref ref-type="bibr" rid="B14">14</xref>] mouse monoclonal antibody (Upstate, Lake Placid, USA, # 05-665), the anti-&#x003b2;-catenin goat polyclonal antibody (above), and anti-actin goat polyclonal antibody (Santa Cruz Biotechnology INC.) were used. After incubation with the appropriate secondary antibodies, bands were visualized using the enhanced chemiluminescence system (GE Healthcare Europe GmbH, Uppsala, Sweden). Membranes were scanned by the ChemiDoc XRS and the band intensities were determined using Quantity One Software (Bio-Rad Laboratories, Inc., Hercules, California, USA).</p></sec><sec><title>Statistical Analyses</title><p>Unpaired <italic>t </italic>test, <italic>z </italic>test, and &#x003c7;<sup>2 </sup>test were used. The data were calculated with Statistica 6 (StatSoft, Tulsa, OK, USA). Values are presented as arithmetrical mean &#x000b1; SEM.</p></sec></sec><sec><title>Results</title><sec><title>Homozygous CTNNB1 Stabilizing Mutation S37A</title><p>DNA sequencing analysis detected the <italic>CTNNB1 </italic>stabilizing mutation S37A (TCT &#x0003e; GCT) in 6 out of the 104 (5.8%) analyzed parathyroid adenomas (Figure <xref ref-type="fig" rid="F1">1</xref>). Constitutional DNA (blood) from 4 out of the 6 patients were available, and encoded the wild-type <italic>CTNNB1 </italic>sequence. The mutations were apparently homozygous by DNA sequencing (Figure <xref ref-type="fig" rid="F1">1</xref>), as we reported previously for 3 out of 20 adenomas [<xref ref-type="bibr" rid="B10">10</xref>]. Taking our previous study into account [<xref ref-type="bibr" rid="B10">10</xref>], a total of 9 out of 124 (7.3%) randomly selected parathyroid adenomas displayed the <italic>CTNNB1 </italic>stabilizing mutation S37A.</p><fig position="float" id="F1"><label>Figure 1</label><caption><p><bold>Representative results of direct DNA sequencing of <italic>CTNNB1 </italic>exon 3</bold>. Constitutional DNA from blood (left panel) and parathyroid adenoma (right panel) of the same pHPT patient.</p></caption><graphic xlink:href="1476-4598-7-53-1"/></fig><p>Homozygosity for the mutation was further substantiated by analytical restriction enzyme digestions. As expected, all 9 fragments harbouring S37A were completely cleaved by Nla III and not by Xma I (Figure <xref ref-type="fig" rid="F2">2A</xref>). Vice versa was observed for fragments with the wild-type codon S37. PCR amplified fragments were used for the DNA sequencing and restriction analyses, and PCR reactions could in theory favour the mutant allele(s). Unbiased PCR reactions were however confirmed by performing PCR amplification in a 1:1 mixture of constitutional DNA and S37A mutant tumor DNA, and by subsequent analytical restriction enzyme digestion (Figure <xref ref-type="fig" rid="F2">2B</xref>).</p><fig position="float" id="F2"><label>Figure 2</label><caption><p><bold>Analytical restriction enzyme cleavage analysis</bold>. (A), <italic>CTNNB1 </italic>exon 3 PCR fragments (176 bp) were digested with Xmn I or Nla III that cuts only wild-type or only S37A mutant sequences, respectively. Three out of the nine parathyroid adenomas with S37A mutation were identified in our previous study [10]. Nla III cuts also outside of codon 37, close to the fragment end (23 bp). U; uncleaved <italic>CTNNB1 </italic>exon 3 PCR fragment. (B), <italic>CTNNB1 </italic>exon 3 was PCR amplified from a 1:1 mixture of constitutional DNA and tumor DNA with the S37A mutation. The fragment was analyzed by restriction enzyme digestions as in (A).</p></caption><graphic xlink:href="1476-4598-7-53-2"/></fig><p>In order to resolve the issue of zygosity for the S37A mutation, 4 tumor DNAs with the corresponding constitutional DNAs were genotyped with the GeneChip 500 K Mapping Array Set (Affymetrix). Gene copy number analysis was done by comparison of informative single-nucleotide polymorphisms (SNPs). Five informative SNPs in <italic>CTNNB1 </italic>and 2 SNPs downstream of the gene showed equal copy number for the 4 paired DNA samples (Table <xref ref-type="table" rid="T1">1</xref>). Thus, taking also the DNA sequencing results into account the S37A mutation was homozygous in these 4 tumours, rather than hemizygous with one mutant and one deleted <italic>CTNNB1 </italic>allele.</p></sec><sec><title>&#x003b2;-catenin Protein Expression</title><p>Previously, we reported aberrant accumulation of &#x003b2;-catenin in all (n = 37) analyzed parathyroid adenomas [<xref ref-type="bibr" rid="B10">10</xref>]. Of the tumors analyzed here by DNA sequencing, 81 frozen parathyroid adenomas, including 6 with the S37A mutation, were of sufficient good quality for immunohistochemical analysis with a &#x003b2;-catenin goat polyclonal peptide antiserum [<xref ref-type="bibr" rid="B10">10</xref>]. The three pHPT tumors with S37A mutation described previously [<xref ref-type="bibr" rid="B10">10</xref>] were also included. In addition to membraneous staining, all 84 tumors displayed distinct cytoplasmic/nuclear immunoreactivity (Figure <xref ref-type="fig" rid="F3">3</xref>). Western blotting analysis was performed to compare the expression level of &#x003b2;-catenin as well as of nonphosphorylated active &#x003b2;-catenin (ratio of &#x003b2;-catenin to actin) in tumors with (n = 8) and without (n = 6) the stabilizing mutation S37A (Figure <xref ref-type="fig" rid="F4">4</xref>). The six tumors without &#x003b2;-catenin stabilizing mutation all expressed the internally truncated LRP5 receptor [<xref ref-type="bibr" rid="B11">11</xref>], and as expected [<xref ref-type="bibr" rid="B10">10</xref>,<xref ref-type="bibr" rid="B11">11</xref>] all fourteen tumors showed accumulation of nonphosphorylated active &#x003b2;-catenin in comparison to normal parathyroid tissue (not shown). A small but significantly higher expression level was observed of both &#x003b2;-catenin and nonphosphorylated active &#x003b2;-catenin in tumors with stabilizing mutation S37A in comparison to those with wild type &#x003b2;-catenin. The ratio of nonphosphorylated active &#x003b2;-catenin to &#x003b2;-catenin was also slightly higher in tumors with &#x003b2;-catenin stabilizing mutation (Figure <xref ref-type="fig" rid="F4">4</xref>). No particular clinical characteristics, including age, sex, serum calcium level, serum PTH level or gland weight related to presence of the S37A mutation.</p><fig position="float" id="F3"><label>Figure 3</label><caption><p><bold>Immunohistochemical analysis of &#x003b2;-catenin</bold>. Immunostaining of 84 parathyroid adenomas with an anti-&#x003b2;-catenin goat polyclonal antibody. The first 9 tumor specimens, of which 3 were described previously [10], displayed <italic>CTNNB1 </italic>homozygous stabilizing mutation S37A. No staining was seen in the absence of primary antibodies (last 4 specimens).</p></caption><graphic xlink:href="1476-4598-7-53-3"/></fig><fig position="float" id="F4"><label>Figure 4</label><caption><p><bold>Western blotting analysis of total and non-phosphorylated active &#x003b2;-catenin</bold>. Eight pHPT tumors with <italic>CTNNB1 </italic>mutation S37A and six pHPT tumors without mutation were analyzed. The group of six tumors expressed the internally truncated LRP5 receptor [11]. All analyzed tumors showed accumulation of active &#x003b2;-catenin in comparison to normal parathyroid tissue (not shown). An anti-active (nonphosphorylated) &#x003b2;-catenin monoclonal antibody [14] and a goat polyclonal antibody with an epitope mapping at the C-terminus of &#x003b2;-catenin were used. Quantisation of the obtained signals are shown below. *, p &#x0003c; 0.05.</p></caption><graphic xlink:href="1476-4598-7-53-4"/></fig></sec></sec><sec><title>Discussion</title><p>We have found that a total of 9 out of 124 (7.3%) randomly selected parathyroid adenomas displayed the <italic>CTNNB1 </italic>stabilizing homozygous mutation S37A. None of these 9 tumors expressed the internally truncated LRP5 receptor [<xref ref-type="bibr" rid="B11">11</xref>] (data not shown), further emphasizing the previous observation that these events are mutually exclusive [<xref ref-type="bibr" rid="B11">11</xref>]. The mutated LRP5 receptor, with the central region deleted, is expressed in the majority of pHPT tumors and is required for accumulation of &#x003b2;-catenin and parathyroid tumor cell growth [<xref ref-type="bibr" rid="B11">11</xref>].</p><p>The S37A <italic>CTNNB1 </italic>mutation commonly occurs also in gastrointestinal carcinoid tumors where 26 out of 29 tumors with mutations harboured S37A [<xref ref-type="bibr" rid="B15">15</xref>]. The mutant protein shows resistance to ubiquination and proteosomal degradation, with a longer half-life than wild-type &#x003b2;-catenin. S37A &#x003b2;-catenin also shows an enhanced affinity for LEF1 and TCF4, its DNA-binding partners in transcriptional regulation [<xref ref-type="bibr" rid="B16">16</xref>-<xref ref-type="bibr" rid="B18">18</xref>]. Homozygous mutation as detected by direct DNA sequencing of <italic>CTNNB1 </italic>seems to be uncommon in other neoplasms, but have been described in a rectal carcinoid tumor and in colorectal cancer [<xref ref-type="bibr" rid="B15">15</xref>,<xref ref-type="bibr" rid="B19">19</xref>]. To be conclusive regarding zygosity, direct DNA sequencing clearly requires low or no contamination of normal cell populations in the tumor sample. In colorectal cancer cells with inactivating <italic>APC </italic>hemizygous mutation or activating <italic>CTNNB1 </italic>heterozygous mutation, the total &#x003b2;-catenin signaling activity seemed dependent also on silencing of <italic>SFRP </italic>genes by promoter hypermethylation with consistent constitutive WNT signaling [<xref ref-type="bibr" rid="B20">20</xref>]. Whether combined activity of two mutant S37A <italic>CTNNB1 </italic>alleles suffices for benign parathyroid tumor growth or whether constitutive WNT signaling is required in addition, remain to be investigated.</p><p>DNA sequence analysis of 24 parathyroid adenomas from Japanese patients revealed no <italic>CTNNB1 </italic>mutations, and immunohistochemistry showed weak cytoplasmic &#x003b2;-catenin staining in 2 tumors [<xref ref-type="bibr" rid="B12">12</xref>]. In another study from Japan (n = 9), cytoplasmic and/or membranous &#x003b2;-catenin staining was seen in 8 adenomas and nuclear staining in one adenoma. DNA sequencing analysis was not done in these specimens [<xref ref-type="bibr" rid="B21">21</xref>]. Furthermore, a recent study did not detect <italic>CTNNB1 </italic>exon 3 mutations in 97 sporadic parathyroid adenomas from patients who had undergone parathyroidectomy in the United States. Unfortunately, &#x003b2;-catenin protein expression was not evaluated in this report [<xref ref-type="bibr" rid="B13">13</xref>]. Since we observed a <italic>CTNNB1 </italic>mutation frequency of 7.3% in adenomas from Swedish patients, this may suggest possible contribution of geographical origin (dietary or environmental differences, or different genetic backgrounds) to mechanisms of parathyroid disease. The <italic>CTNNB1 </italic>mutation frequency vary considerably also in colorectal cancer (1&#x02013;60%) and melanomas (0.02&#x02013;27%), apparently not related to geographical origin [<xref ref-type="bibr" rid="B8">8</xref>,<xref ref-type="bibr" rid="B17">17</xref>,<xref ref-type="bibr" rid="B22">22</xref>-<xref ref-type="bibr" rid="B30">30</xref>]. The observations may be attributed to the stochastic distribution of probability in analyzed material or to other causalities, like that the tumor sample purity and pathology must be guaranteed.</p></sec><sec><title>Conclusion</title><p>By analyzing a large series of tumors from Swedish patients, this study further emphasizes &#x003b2;-catenin accumulation as the most common aberration in parathyroid tumors of primary origin. <italic>CTNNB1</italic>-stabilizing mutations were found in 5.8% of the tumors, or in 7.3% when taking our previous study [<xref ref-type="bibr" rid="B10">10</xref>] into account. The WNT/&#x003b2;-catenin signaling pathway, with &#x003b2;-catenin and the internally truncated LRP5 receptor [<xref ref-type="bibr" rid="B11">11</xref>] in particular, present therapeutic targets for hyperparathyroidism.</p></sec><sec><title>Competing interests</title><p>The authors declare that they have no competing interests.</p></sec><sec><title>Authors' contributions</title><p>PB participated in the design of the study, performed experiments, analyzed data and performed the statistical analysis, DL analyzed the data, G&#x000c5; helped to draft the manuscript, GW conceived of the study, participated in its design and coordination and drafted the manuscript. All authors read and approved the final manuscript.</p></sec></body><back><ack><sec><title>Acknowledgements</title><p>This work was supported by the Swedish Research Council and Swedish Cancer Society. We thank the referee of another paper for suggesting the use of Xma I and Nla III. We are grateful to Birgitta Bondeson and Peter Lillhager for skilful technical assistance. We are also grateful to Marika R&#x000f6;nnholm at the Bioinformatics and Expression Analysis core facility at NOVUM, Karolinska Institute, Huddinge, Sweden.</p></sec></ack><ref-list><ref id="B1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Marx</surname><given-names>S</given-names></name></person-group><article-title>Hyperparathyroid and hypoparathyroid disorders</article-title><source>N Engl J Med</source><year>2000</year><volume>343</volume><fpage>1863</fpage><lpage>1875</lpage><pub-id pub-id-type="pmid">11117980</pub-id><pub-id pub-id-type="doi">10.1056/NEJM200012213432508</pub-id></citation></ref><ref id="B2"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Arnold</surname><given-names>A</given-names></name><name><surname>Shattuck</surname><given-names>TM</given-names></name><name><surname>Mallya</surname><given-names>SM</given-names></name><name><surname>Krebs</surname><given-names>LJ</given-names></name><name><surname>Costa</surname><given-names>J</given-names></name><name><surname>Gallagher</surname><given-names>J</given-names></name><name><surname>Wild</surname><given-names>Y</given-names></name><name><surname>Saucier</surname><given-names>K</given-names></name></person-group><article-title>Molecular pathogenesis of primary hyperparathyroidism</article-title><source>J Bone Miner Res</source><year>2002</year><volume>17</volume><fpage>N30</fpage><lpage>36</lpage><pub-id pub-id-type="pmid">12412775</pub-id></citation></ref><ref id="B3"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>&#x000c5;kerstr&#x000f6;m</surname><given-names>G</given-names></name><name><surname>Hellman</surname><given-names>P</given-names></name></person-group><article-title>Primary hyperparathyroidism</article-title><source>Curr Opin Oncol</source><year>2004</year><volume>16</volume><fpage>1</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">14685084</pub-id><pub-id pub-id-type="doi">10.1097/00001622-200401000-00002</pub-id></citation></ref><ref id="B4"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>&#x000c5;kerstr&#x000f6;m</surname><given-names>G</given-names></name><name><surname>Hellman</surname><given-names>P</given-names></name><name><surname>Hessman</surname><given-names>O</given-names></name><name><surname>Segersten</surname><given-names>U</given-names></name><name><surname>Westin</surname><given-names>G</given-names></name></person-group><article-title>Parathyroid glands in calcium regulation and human disease</article-title><source>Ann N Y Acad Sci</source><year>2005</year><volume>1040</volume><fpage>53</fpage><lpage>58</lpage><pub-id pub-id-type="pmid">15891005</pub-id><pub-id pub-id-type="doi">10.1196/annals.1327.005</pub-id></citation></ref><ref id="B5"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Polakis</surname><given-names>P</given-names></name></person-group><article-title>The oncogenic activation of &#x003b2;-catenin</article-title><source>Curr Opin Genet Dev</source><year>1999</year><volume>9</volume><fpage>15</fpage><lpage>21</lpage><pub-id pub-id-type="pmid">10072352</pub-id><pub-id pub-id-type="doi">10.1016/S0959-437X(99)80003-3</pub-id></citation></ref><ref id="B6"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lustig</surname><given-names>B</given-names></name><name><surname>Behrens</surname><given-names>J</given-names></name></person-group><article-title>The Wnt signaling pathway and its role in tumor development</article-title><source>J Cancer Res Clin Oncol</source><year>2003</year><volume>129</volume><fpage>199</fpage><lpage>221</lpage><pub-id pub-id-type="pmid">12707770</pub-id></citation></ref><ref id="B7"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Giles</surname><given-names>RH</given-names></name><name><surname>van Es</surname><given-names>JH</given-names></name><name><surname>Clevers</surname><given-names>H</given-names></name></person-group><article-title>Caught up in a Wnt storm: Wnt signaling in cancer</article-title><source>Biochim Biophys Acta</source><year>2003</year><volume>1653</volume><fpage>1</fpage><lpage>24</lpage><pub-id pub-id-type="pmid">12781368</pub-id></citation></ref><ref id="B8"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Polakis</surname><given-names>P</given-names></name></person-group><article-title>The many ways of Wnt in cancer</article-title><source>Curr Opin Genet Dev</source><year>2007</year><volume>17</volume><fpage>45</fpage><lpage>51</lpage><pub-id pub-id-type="pmid">17208432</pub-id><pub-id pub-id-type="doi">10.1016/j.gde.2006.12.007</pub-id></citation></ref><ref id="B9"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Major</surname><given-names>MB</given-names></name><name><surname>Camp</surname><given-names>ND</given-names></name><name><surname>Berndt</surname><given-names>JD</given-names></name><name><surname>Yi</surname><given-names>X</given-names></name><name><surname>Goldenberg</surname><given-names>SJ</given-names></name><name><surname>Hubbert</surname><given-names>C</given-names></name><name><surname>Biechele</surname><given-names>TL</given-names></name><name><surname>Gingras</surname><given-names>AC</given-names></name><name><surname>Zheng</surname><given-names>N</given-names></name><name><surname>Maccoss</surname><given-names>MJ</given-names></name><name><surname>Angers</surname><given-names>S</given-names></name><name><surname>Moon</surname><given-names>RT</given-names></name></person-group><article-title>Wilms tumor suppressor WTX negatively regulates WNT/&#x003b2;-catenin signaling</article-title><source>Science</source><year>2007</year><volume>316</volume><fpage>1043</fpage><lpage>1046</lpage><pub-id pub-id-type="pmid">17510365</pub-id><pub-id pub-id-type="doi">10.1126/science/1141515</pub-id></citation></ref><ref id="B10"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bj&#x000f6;rklund</surname><given-names>P</given-names></name><name><surname>&#x000c5;kerstr&#x000f6;m</surname><given-names>G</given-names></name><name><surname>Westin</surname><given-names>G</given-names></name></person-group><article-title>Accumulation of nonphosphorylated &#x003b2;-catenin and c-myc in primary and uremic secondary hyperparathyroid tumors</article-title><source>J Clin Endocrinol Metab</source><year>2007</year><volume>92</volume><fpage>338</fpage><lpage>344</lpage><pub-id pub-id-type="pmid">17047023</pub-id><pub-id pub-id-type="doi">10.1210/jc.2006-1197</pub-id></citation></ref><ref id="B11"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bj&#x000f6;rklund</surname><given-names>P</given-names></name><name><surname>&#x000c5;kerstr&#x000f6;m</surname><given-names>G</given-names></name><name><surname>Westin</surname><given-names>G</given-names></name></person-group><article-title>An LRP5 receptor with internal deletion in hyperparathyroid tumors with implications for deregulated WNT/&#x003b2;-catenin signaling</article-title><source>PLoS Med</source><year>2007</year><volume>4</volume><fpage>e328</fpage><pub-id pub-id-type="pmid">18044981</pub-id><pub-id pub-id-type="doi">10.1371/journal.pmed.0040328</pub-id></citation></ref><ref id="B12"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ikeda</surname><given-names>S</given-names></name><name><surname>Ishizaki</surname><given-names>Y</given-names></name><name><surname>Shimizu</surname><given-names>Y</given-names></name><name><surname>Fujimori</surname><given-names>M</given-names></name><name><surname>Ojima</surname><given-names>Y</given-names></name><name><surname>Okajima</surname><given-names>M</given-names></name><name><surname>Sugino</surname><given-names>K</given-names></name><name><surname>Asahara</surname><given-names>T</given-names></name></person-group><article-title>Immunohistochemistry of cyclin D1 and &#x003b2;-catenin, and mutational analysis of exon 3 of &#x003b2;-catenin gene in parathyroid tumors</article-title><source>Int J Oncol</source><year>2002</year><volume>20</volume><fpage>463</fpage><lpage>466</lpage><pub-id pub-id-type="pmid">11836555</pub-id></citation></ref><ref id="B13"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Costa-Guda</surname><given-names>J</given-names></name><name><surname>Arnold</surname><given-names>A</given-names></name></person-group><article-title>Absence of stabilizing mutations of &#x003b2;-catenin encoded by CTNNB1 exon 3 in a large series of sporadic parathyroid adenomas</article-title><source>J Clin Endocrinol Metab</source><year>2007</year><volume>92</volume><fpage>1564</fpage><lpage>1566</lpage><pub-id pub-id-type="pmid">17284619</pub-id><pub-id pub-id-type="doi">10.1210/jc.2006-2554</pub-id></citation></ref><ref id="B14"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>van Noort</surname><given-names>M</given-names></name><name><surname>Meeldijk</surname><given-names>J</given-names></name><name><surname>Zee</surname><given-names>R van der</given-names></name><name><surname>Destree</surname><given-names>O</given-names></name><name><surname>Clevers</surname><given-names>H</given-names></name></person-group><article-title>Wnt signaling controls the phosphorylation status of beta-catenin</article-title><source>J Biol Chem</source><year>2002</year><volume>277</volume><fpage>17901</fpage><lpage>17905</lpage><pub-id pub-id-type="pmid">11834740</pub-id><pub-id pub-id-type="doi">10.1074/jbc.M111635200</pub-id></citation></ref><ref id="B15"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fujimori</surname><given-names>M</given-names></name><name><surname>Ikeda</surname><given-names>S</given-names></name><name><surname>Shimizu</surname><given-names>Y</given-names></name><name><surname>Okajima</surname><given-names>M</given-names></name><name><surname>Asahara</surname><given-names>T</given-names></name></person-group><article-title>Accumulation of &#x003b2;-catenin protein and mutations in exon 3 of &#x003b2;-catenin gene in gastrointestinal carcinoid tumor</article-title><source>Cancer Res</source><year>2001</year><volume>61</volume><fpage>6656</fpage><lpage>6659</lpage><pub-id pub-id-type="pmid">11559529</pub-id></citation></ref><ref id="B16"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Orford</surname><given-names>K</given-names></name><name><surname>Crockett</surname><given-names>C</given-names></name><name><surname>Jensen</surname><given-names>JP</given-names></name><name><surname>Weissman</surname><given-names>AM</given-names></name><name><surname>Byers</surname><given-names>SW</given-names></name></person-group><article-title>Serine phosphorylation-regulated ubiquitination and degradation of &#x003b2;-catenin</article-title><source>J Biol Chem</source><year>1997</year><volume>272</volume><fpage>24735</fpage><lpage>24738</lpage><pub-id pub-id-type="pmid">9312064</pub-id><pub-id pub-id-type="doi">10.1074/jbc.272.40.24735</pub-id></citation></ref><ref id="B17"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rubinfeld</surname><given-names>B</given-names></name><name><surname>Robbins</surname><given-names>P</given-names></name><name><surname>El-Gamil</surname><given-names>M</given-names></name><name><surname>Albert</surname><given-names>I</given-names></name><name><surname>Porfiri</surname><given-names>E</given-names></name><name><surname>Polakis</surname><given-names>P</given-names></name></person-group><article-title>Stabilization of &#x003b2;-catenin by genetic defects in melanoma cell lines</article-title><source>Science</source><year>1997</year><volume>275</volume><fpage>1790</fpage><lpage>1792</lpage><pub-id pub-id-type="pmid">9065403</pub-id><pub-id pub-id-type="doi">10.1126/science.275.5307.1790</pub-id></citation></ref><ref id="B18"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Williams</surname><given-names>BO</given-names></name><name><surname>Barish</surname><given-names>GD</given-names></name><name><surname>Klymkowsky</surname><given-names>MW</given-names></name><name><surname>Varmus</surname><given-names>HE</given-names></name></person-group><article-title>A comparative evaluation of &#x003b2;-catenin and plakoglobin signaling activity</article-title><source>Oncogene</source><year>2000</year><volume>19</volume><fpage>5720</fpage><lpage>5728</lpage><pub-id pub-id-type="pmid">11126358</pub-id><pub-id pub-id-type="doi">10.1038/sj.onc.1203921</pub-id></citation></ref><ref id="B19"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ilyas</surname><given-names>M</given-names></name><name><surname>Tomlinson</surname><given-names>IPM</given-names></name><name><surname>Rowan</surname><given-names>A</given-names></name><name><surname>Pignatelli</surname><given-names>M</given-names></name><name><surname>Bodmer</surname><given-names>WF</given-names></name></person-group><article-title>&#x003b2;-Catenin mutations in cell lines established from human colorectal cancers</article-title><source>Proc Natl Acad Sci USA</source><year>1997</year><volume>94</volume><fpage>10330</fpage><lpage>10334</lpage><pub-id pub-id-type="pmid">9294210</pub-id><pub-id pub-id-type="doi">10.1073/pnas.94.19.10330</pub-id></citation></ref><ref id="B20"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Suzuki</surname><given-names>H</given-names></name><name><surname>Watkins</surname><given-names>DN</given-names></name><name><surname>Jair</surname><given-names>KW</given-names></name><name><surname>Schuebel</surname><given-names>KE</given-names></name><name><surname>Markowitz</surname><given-names>SD</given-names></name><name><surname>Chen</surname><given-names>WD</given-names></name><name><surname>Pretlow</surname><given-names>TP</given-names></name><name><surname>Yang</surname><given-names>B</given-names></name><name><surname>Akiyama</surname><given-names>Y</given-names></name><name><surname>Van Engeland</surname><given-names>M</given-names></name><name><surname>Toyota</surname><given-names>M</given-names></name><name><surname>Tokino</surname><given-names>T</given-names></name><name><surname>Hinoda</surname><given-names>Y</given-names></name><name><surname>Imai</surname><given-names>K</given-names></name><name><surname>Herman</surname><given-names>JG</given-names></name><name><surname>Baylin</surname><given-names>SB</given-names></name></person-group><article-title>Epigenetic inactivation of SFRP genes allows constitutive WNT signaling in colorectal cancer</article-title><source>Nat Genet</source><year>2004</year><volume>36</volume><fpage>417</fpage><lpage>422</lpage><pub-id pub-id-type="pmid">15034581</pub-id><pub-id pub-id-type="doi">10.1038/ng1330</pub-id></citation></ref><ref id="B21"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Semba</surname><given-names>S</given-names></name><name><surname>Kusumi</surname><given-names>R</given-names></name><name><surname>Moriya</surname><given-names>T</given-names></name><name><surname>Sasano</surname><given-names>H</given-names></name></person-group><article-title>Nuclear accumulation of &#x003b2;-catenin in human endocrine tumors: Association with Ki-67 (MIB-1) proliferative activity</article-title><source>Endocr Pathol</source><year>2000</year><volume>11</volume><fpage>243</fpage><lpage>250</lpage><pub-id pub-id-type="pmid">12114696</pub-id><pub-id pub-id-type="doi">10.1385/EP:11:3:243</pub-id></citation></ref><ref id="B22"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Morin</surname><given-names>PJ</given-names></name><name><surname>Sparks</surname><given-names>AB</given-names></name><name><surname>Korinek</surname><given-names>V</given-names></name><name><surname>Barker</surname><given-names>N</given-names></name><name><surname>Clevers</surname><given-names>H</given-names></name><name><surname>Vogelstein</surname><given-names>B</given-names></name><name><surname>Kinzler</surname><given-names>KW</given-names></name></person-group><article-title>Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC</article-title><source>Science</source><year>1997</year><volume>275</volume><fpage>1787</fpage><lpage>1790</lpage><pub-id pub-id-type="pmid">9065402</pub-id><pub-id pub-id-type="doi">10.1126/science.275.5307.1787</pub-id></citation></ref><ref id="B23"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sparks</surname><given-names>AB</given-names></name><name><surname>Morin</surname><given-names>PJ</given-names></name><name><surname>Vogelstein</surname><given-names>B</given-names></name><name><surname>Kinzler</surname><given-names>KW</given-names></name></person-group><article-title>Mutational analysis of the APC/beta-catenin/Tcf pathway in colorectal cancer</article-title><source>Cancer Res</source><year>1998</year><volume>58</volume><fpage>1130</fpage><lpage>1134</lpage><pub-id pub-id-type="pmid">9515795</pub-id></citation></ref><ref id="B24"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Omholt</surname><given-names>K</given-names></name><name><surname>Platz</surname><given-names>A</given-names></name><name><surname>Ringborg</surname><given-names>U</given-names></name><name><surname>Hansson</surname><given-names>J</given-names></name></person-group><article-title>Cytoplasmic and nuclear accumulation of beta-catenin is rarely caused by CTNNB1 exon 3 mutations in cutaneous malignant melanoma</article-title><source>Int J Cancer</source><year>2001</year><volume>92</volume><fpage>839</fpage><lpage>842</lpage><pub-id pub-id-type="pmid">11351304</pub-id><pub-id pub-id-type="doi">10.1002/ijc.1270</pub-id></citation></ref><ref id="B25"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Reifenberger</surname><given-names>J</given-names></name><name><surname>Knobbe</surname><given-names>CB</given-names></name><name><surname>Wolter</surname><given-names>M</given-names></name><name><surname>Blaschke</surname><given-names>B</given-names></name><name><surname>Schulte</surname><given-names>KW</given-names></name><name><surname>Pietsch</surname><given-names>T</given-names></name><name><surname>Ruzicka</surname><given-names>T</given-names></name><name><surname>Reifenberger</surname><given-names>G</given-names></name></person-group><article-title>Molecular genetic analysis of malignant melanomas for aberrations of the WNT signaling pathway genes CTNNB1, APC, ICAT and BTRC</article-title><source>Int J Cancer</source><year>2002</year><volume>100</volume><fpage>549</fpage><lpage>556</lpage><pub-id pub-id-type="pmid">12124804</pub-id><pub-id pub-id-type="doi">10.1002/ijc.10512</pub-id></citation></ref><ref id="B26"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pollock</surname><given-names>PM</given-names></name><name><surname>Hayward</surname><given-names>N</given-names></name></person-group><article-title>Mutations in exon 3 of the beta-catenin gene are rare in melanoma cell lines</article-title><source>Melanoma Res</source><year>2002</year><volume>12</volume><fpage>183</fpage><lpage>186</lpage><pub-id pub-id-type="pmid">11930117</pub-id><pub-id pub-id-type="doi">10.1097/00008390-200204000-00013</pub-id></citation></ref><ref id="B27"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Demunter</surname><given-names>A</given-names></name><name><surname>Libbrecht</surname><given-names>L</given-names></name><name><surname>Degreef</surname><given-names>H</given-names></name><name><surname>De Wolf-Peeters</surname><given-names>C</given-names></name><name><surname>Oord</surname><given-names>JJ van den</given-names></name></person-group><article-title>Loss of membranous expression of beta-catenin is associated with tumor progression in cutaneous melanoma and rarely caused by exon 3 mutations</article-title><source>Mod Pathol</source><year>2002</year><volume>15</volume><fpage>454</fpage><lpage>461</lpage><pub-id pub-id-type="pmid">11950921</pub-id><pub-id pub-id-type="doi">10.1038/modpathol.3880546</pub-id></citation></ref><ref id="B28"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Johnson</surname><given-names>V</given-names></name><name><surname>Volikos</surname><given-names>E</given-names></name><name><surname>Halford</surname><given-names>SE</given-names></name><name><surname>Eftekhar Sadat</surname><given-names>ET</given-names></name><name><surname>Popat</surname><given-names>S</given-names></name><name><surname>Talbot</surname><given-names>I</given-names></name><name><surname>Truninger</surname><given-names>K</given-names></name><name><surname>Martin</surname><given-names>J</given-names></name><name><surname>Jass</surname><given-names>J</given-names></name><name><surname>Houlston</surname><given-names>R</given-names></name><name><surname>Atkin</surname><given-names>W</given-names></name><name><surname>Tomlinson</surname><given-names>IPM</given-names></name><name><surname>Silver</surname><given-names>ARJ</given-names></name></person-group><article-title>Exon 3 beta-catenin mutations are specifically associated with colorectal carcinomas in hereditary non-polyposis colorectal cancer syndrome</article-title><source>Gut</source><year>2005</year><volume>54</volume><fpage>264</fpage><lpage>267</lpage><pub-id pub-id-type="pmid">15647192</pub-id><pub-id pub-id-type="doi">10.1136/gut.2004.048132</pub-id></citation></ref><ref id="B29"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Luchtenborg</surname><given-names>M</given-names></name><name><surname>Weijenberg</surname><given-names>MP</given-names></name><name><surname>Wark</surname><given-names>PA</given-names></name><name><surname>Saritas</surname><given-names>AM</given-names></name><name><surname>Roemen</surname><given-names>GM</given-names></name><name><surname>van Muijen</surname><given-names>GN</given-names></name><name><surname>de Bruine</surname><given-names>AP</given-names></name><name><surname>Brandt</surname><given-names>PA van den</given-names></name><name><surname>de Goeij</surname><given-names>AF</given-names></name></person-group><article-title>Mutations in APC, CTNNB1 and K-ras genes and expression of hMLH1 in sporadic colorectal carcinomas from the Netherlands Cohort Study</article-title><source>BMC Cancer</source><year>2005</year><volume>5</volume><fpage>160</fpage><pub-id pub-id-type="pmid">16356174</pub-id><pub-id pub-id-type="doi">10.1186/1471-2407-5-160</pub-id></citation></ref><ref id="B30"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Thorstensen</surname><given-names>L</given-names></name><name><surname>Lind</surname><given-names>GE</given-names></name><name><surname>Lovig</surname><given-names>T</given-names></name><name><surname>Diep</surname><given-names>CB</given-names></name><name><surname>Meling</surname><given-names>GI</given-names></name><name><surname>Rognum</surname><given-names>TO</given-names></name><name><surname>Lothe</surname><given-names>RA</given-names></name></person-group><article-title>Genetic and epigenetic changes of components affecting the WNT pathway in colorectal carcinomas stratified by microsatellite instability</article-title><source>Neoplasia</source><year>2005</year><volume>7</volume><fpage>99</fpage><lpage>108</lpage><pub-id pub-id-type="pmid">15802015</pub-id><pub-id pub-id-type="doi">10.1593/neo.04448</pub-id></citation></ref></ref-list></back></article> 